Specialty Sales Representative – Cardiometabolic Rare Disease

Description

Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) is a clinical stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics.

Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.

Arrowhead’s corporate headquarters is in Pasadena, CA with research and development teams in Madison, WI and San Diego, CA. Our employees are nimble, science‑driven innovators who are collaborating to bring new therapies to patients in need.

Arrowhead Pharmaceuticals is seeking experienced, high‑performing, and driven Specialty Sales Representatives to join our expanding commercial organization. This is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high‑need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). This role is critical to delivering launch excellence by driving prescriber activation, accelerating therapy adoption, and ensuring sustained utilization within complex healthcare environments.

The Specialty Sales Representative will operate with strategic agility, strong clinical acumen, and disciplined execution to positively impact patient outcomes.

• Develop and execute comprehensive, data‑driven territory business plans aligned to brand strategy and launch objectives.
• Analyze territory data (prescribing trends, account potential, access landscape) to identify growth opportunities and prioritize high‑value targets.
• Manage territory budget responsibly, including speaker programs and promotional initiatives.
• Consistently achieve or exceed sales goals and performance metrics.

• Deliver compelling, compliant, and clinically accurate product education within approved labeling.
• Articulate complex clinical data and value propositions tailored to cardiologists, lipid specialists, endocrinologists, and targeted PCPs.
• Differentiating Arrowhead therapies within a competitive and evolving cardiometabolic landscape.
• Execute speaker programs, educational events, and peer‑to‑peer engagements to drive awareness and adoption.
• Support appropriate patient identification and therapy initiation through thoughtful provider engagement.

• Build and sustain strong, trust‑based relationships with healthcare professionals, office staff, and institutional stakeholders.
• Navigate complex health systems and coordinate effectively within IDNs in partnership with Key Account Managers.
• Identify access barriers and collaborate with Market Access and patient services to support pull‑through.
• Maintain consistent, high‑quality engagement and service across accounts to drive durable utilization.

• Partner closely with Marketing, Medical Affairs, Market Access, Health IT, and Patient Services to align territory execution with enterprise strategy.
• Provide actionable field insights regarding market dynamics,…